Biomarkers in rare neuromuscular diseases

Experimental Cell Research

Volumn 325, Issue 1, 2014, Pages 44-49

  Scotton, Chiara ^a   Passarelli, Chiara ^b   Neri, Marcella ^a   Ferlini, Alessandra ^a  

^a UNIVERSITY OF FERRARA   (Italy)

^b BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

Author keywords

Biomarker discovery; Diagnostic prognostic biomarker; Neuromuscular diseases; Personalized medicine; Predictive therapeutic biomarkers

Indexed keywords

BIOLOGICAL MARKER; DNA; MICRORNA; PROTEOME; TENASCIN;

CLINICAL ASSESSMENT; COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; EVALUATION STUDY; FOLLOW UP; GENOMICS; HUMAN; IMMUNOASSAY; NEUROMUSCULAR DISEASE; PRIORITY JOURNAL; PROGNOSIS; PROTEOMICS; RARE DISEASE; REVIEW; TREATMENT RESPONSE;

BIOMARKER DISCOVERY; DIAGNOSTIC/PROGNOSTIC BIOMARKER; NEUROMUSCULAR DISEASES; PERSONALIZED MEDICINE; PREDICTIVE/THERAPEUTIC BIOMARKERS;

ANIMALS; BIOLOGICAL MARKERS; GENETIC MARKERS; HUMANS; NEUROMUSCULAR DISEASES; PROTEOME;

EID: 84901832895     PISSN: 00144827     EISSN: 10902422     Source Type: Journal    
DOI: 10.1016/j.yexcr.2013.12.020     Document Type: Review

References (21)

1. Vasli N., Laporte J. Impacts of massively parallel sequencing for genetic diagnosis of neuromuscular disorders. Acta Neuropathol. 2013, 125(2):173-185. 10.1007/s00401-012-1072-7.
2. McDonald C.M. Clinical approach to the diagnostic evaluation of hereditary and acquired neuromuscular diseases. Phys. Med. Rehabil. Clin. N. Am. 2012, 23(3):495-563. 10.1016/j.pmr.2012.06.011.
3. Kaplan J.C. The 2012 version of the gene table of monogenic neuromuscular disorders. Neuromuscul. Disord. 2011, 21(12):833-861.
4. Atkinson A.J., Colburn W.A., DeGruttola V.G., DeMets D.L., Downing G.J., Hoth D.F., Oates J.A., Peck C.C., Schooley R.T., Spilker B.A., Woodcock J., Zeger S.L. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin. Pharmacol. Ther. 2001, 69:89-95.
5. Finkel R.S., Crawford T.O., Swoboda K.J., Kaufmann P., Juhasz P., Li X., Guo Y., Li R.H., Trachtenberg F., Forrest S.J., Kobayashi D.T., Chen K.S., Joyce C.L., Plasterer T. Candidate proteins, metabolites and transcripts in the biomarkers for spinal muscular atrophy (BforSMA) clinical study. PLoS One 2012, 7(4):e35462. 10.1371/journal.pone.0035462.
6. EMA: Qualification opinion of Alzheimer's disease novel methodologies/biomarkers for PET amyloid imaging (positive/negative) as a biomarker for enrichment for use - in predementia AD clinical trials, 2011, EMA/CHMP/SAWP/892998/2011.
7. Ma Q., Lu A.Y. Pharmacogenetics, pharmacogenomics, and individualized medicine. Pharmacol. Rev. 2011, 63(2):437-459. 10.1124/pr.110.003533.
8. Mizuno H., Nakamura A., Aoki Y., Ito N., Kishi S., Yamamoto K., Sekiguchi M., Takeda S., Hashido K. Identification of muscle-specific microRNAs in serum of muscular dystrophy animal models: promising novel blood-based markers for muscular dystrophy. PLoS One 2011, 6(3):e18388. (Mar. 30). 10.1371/journal.pone.0018388.
9. Eisenberg I., Alexander M.S., Kunkel L.M. miRNAS in normal and diseased skeletal muscle. J. Cell Mol. Med. 2009, 13(1):2-11. 10.1111/j.
10. Evans-Galea M.V., Carrodus N, Rowley S.M., Corben L.A., Tai G., Saffery R., Galati J.C., Wong N.C., Craig J.M., Lynch D.R., Regner S.R., Brocht A.F., Perlman SL, Bushara K.O., Gomez C.M., Wilmot G.R., Li L., Varley E., Delatycki M.B., Sarsero J.P. FXN methylation predicts expression and clinical outcome in Friedreich ataxia. Ann. Neurol. 2012, 71(4):487-497. 10.1002/ana.22671.
11. Niebroj-Dobosz I., Madej-Pilarczyk A., Marchel M., Sokołowska B., Hausmanowa-Petrusewicz I. Circulating tenascin-C levels in patients with dilated cardiomyopathy in the course of Emery-Dreifuss muscular dystrophy. Clin. Chim. Acta 2011, 412(17-18):1533-1538. 10.1016/j.cca.2011.04.033.
12. Kobayashi D.T., Shi J., Stephen L., Ballard K.L., Dewey R, Mapes J., Chung B., McCarthy K., Swoboda K.J., Crawford T.O., Li R., Plasterer T., Joyce C, Biomarkers for Spinal Muscular Atrophy Study Group, Chung W.K., Kaufmann P., Darras B.T., Finkel R.S., Sproule D.M., Martens W.B., McDermott M.P., De Vivo D.C., Pediatric Neuromuscular Clinical Research Network, Walker M.G., Chen K.S. SMA-MAP: a plasma protein panel for spinal muscular atrophy. PLoS One 2013, 8(4):e60113.
13. Nardo G., Pozzi S., Pignataro M., Lauranzano E., Spano G., Garbelli S., Mantovani S., Marinou K., Papetti L., Monteforte M., Torri V., Paris L., Bazzoni G., Lunetta C., Corbo M., Mora G., Bendotti C., Bonetto V. Amyotrophic lateral sclerosis multiprotein biomarkers in peripheral blood mononuclear cells. PLoS One 2011, 6(10):e25545. 10.1371/journal.pone.0025545.
14. Ganesalingam J., Bowser R. The application of biomarkers in clinical trials for motor neuron disease. Biomark. Med. 2010, 4(2):281-297. 10.2217/bmm.09.71.
15. Nadarajah V.D., van Putten M., Chaouch A., Garrood P., Straub V., Lochmüller H., Ginjaar H.B., Aartsma-Rus A.M., van Ommen G.J., den Dunnen J.T., 't Hoen P.A. Serum matrix metalloproteinase-9 (MMP-9) as a biomarker for monitoring disease progression in Duchenne muscular dystrophy (DMD). Neuromuscul. Disord. 2011, 21(8):569-578. 10.1016/j.nmd.2011.05.011.
16. Kinali M., Arechavala-Gomeza V., Cirak S., Glover A., Guglieri M., Feng L., Hollingsworth K.G., Hunt D., Jungbluth H., Roper H.P., Quinlivan R.M., Gosalakkal J.A., Jayawant S., Nadeau A., Hughes-Carre L., Manzur A.Y., Mercuri E., Morgan J.E., Straub V., Bushby K., Sewry C., Rutherford M., Muntoni F. Muscle histology vs MRI in Duchenne muscular dystrophy. Neurology 2011, 76(4):346-353. (Jan. 25). 10.1212/WNL.0b013e318208811f.
17. Vucic S., Nicholson G.A., Kiernan M.C. Cortical hyperexcitability may precede the onset of familial amyotrophic lateral sclerosis. Brain 2008, 131(Pt 6):1540-1550. 10.1093/brain/awn071.
18. Aggarwal A., Nicholson G. Detection of preclinical motor neurone loss in SOD1 mutation carriers using motor unit number estimation. J. Neurol. Neurosurg. Psychiatry 2002, 73(2):199-201.
19. Wei C.Y., Lee M.T., Chen Y.T. Pharmacogenomics of adverse drug reactions: implementing personalized medicine. Hum. Mol. Genet. 2012, 21(R1):R58-R65. (Oct. 15).
20. Kotelnikova E., Shkrob M.A., Pyatnitskiy M.A., Ferlini A., Daraselia N. Novel approach to meta-analysis of microarray datasets reveals muscle remodeling-related drug targets and biomarkers in Duchenne muscular dystrophy. PLoS Comput. Biol. 2012, 8(2):e1002365. 10.1371/journal.pcbi.1002365.
21. Chen R., Mias G.I., Li-Pook-Than J., Jiang L., Lam H.Y., Chen R., Miriami E., Karczewski K.J., Hariharan M., Dewey F.E., Cheng Y., Clark M.J., Im H., Habegger L., Balasubramanian S., O'huallachain M., Dudley J.T., Hillenmeyer S., Haraksingh R., Sharon D., Euskirchen G., Lacroute P., Bettinger K., Boyle A.P., Kasowski M., Grubert F., Seki S., Garcia M., Whirl-Carrillo M., Gallardo M., Blasco M.A., Greenberg P.L., Snyder P., Klein T.E., Altman R.B., Butte A.J., Ashley E.A., Gerstein M., Nadeau K.C., Tang H., Snyder M. Personal omics profiling reveals dynamic molecular and medical phenotypes. Cell 2012 Mar 16, 148(6):1293-1307. 10.1016/j.cell.